The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Western medicine has typically had little to offer those with end stage liver disease, which can be marked by advanced cancer and irregular liver function. In the following press release, you will learn more about a recently announced Phase 1 study examining the effects an experimental drug has on this serious combination of conditions.
Continue reading »Designed to have more anti-viral and immune-stimulating activity, Maxy-alpha is Roche's next generation interferon alpha for Hepatitis C treatment. Roche has initiated a Phase 1a study to determine the safety and efficacy of this drug.
Continue reading »Although sharing contaminated needles for illicit drug use is the most common way of transmitting the Hepatitis C virus, many physicians are hesitant to administer treatment to active drug users. New research demonstrates how drug users are just as likely to clear the virus as non-drug users, which will likely change this prescribing trend and help reduce the spread of the disease.
Continue reading »When two separate studies produce identical results, medical innovations quickly follow. Researchers from Scripps Institute and La Jolla Institute for Allergy and Immunology have come to the same conclusion: Altering a specific immune system molecule allows a rat to successfully fight Hepatitis C. If these findings can be reproduced in humans, an entirely new way to eradicate Hepatitis C may be on the horizon.
Continue reading »American college students are not sufficiently educated about Hepatitis C, according to a recent study. A startling percentage of surveyed students are at risk for contracting the virus due to some fairly common college activities. If you have a loved one who is an undergraduate student, you will want to send them this link to discover the risk factors for their own protection.
Continue reading »Two leading companies are merging in an effort to accelerate Hepatitis C treatments. The goal of this collaboration is to further the development of Hepatitis C protease inhibitors.
Continue reading »Currently in a Phase 2b clinical trial to evaluate its efficacy, safety and quality of life effects, HCV participants on AlbuferonTM with Ribavirin are showing positive results. Compared to one of the most popular treatment options available, interim trial results after 12 weeks show more favorable life markers with this new drug combination.
Continue reading »Granted fast track status, Roche's® R1626 is beginning a Phase II study to evaluate its safety and HCV anti-viral activity. Administered in combination with PEGASYS® and COPEGUS®, this trial is now enrolling people with HCV genotype 1 who have previously not received treatment.
Continue reading »Nearly 1,300 people with Hepatitis C genotype 1, the most common strain in the US, will be testing a new drug in a Phase III trial. The new drug, Albuferon, will be compared with the current gold standards of HCV treatment, PEGASYS® and PEG-IFN alpha 2a.
Continue reading »When undergoing interferon/ribavirin treatment for Hepatitis C, being able to judge the treatment's chance of success is critical in deciding whether to continue. By increasing an RNA test's sensitivity, American researchers have found a more reliable method for physicians to judge treatment outcome.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
